TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies. Overall survival in patients who received checkpoint inhibitors ...
Immune monitoring of phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results